Graphic showing an MRI scan of a meningioma. Text banner with the publication citation reads, Prospective Genomic Profiling of Consecutive Meningiomas. Nguyen MP, Mirchia K, Braman BC, et al. (2026) JAMA Oncol.

New in @jamaoncology.com: a UCSF team led by David Raleigh, MD, PhD, reports on a prospective genomic profiling analysis of more than 1100 #meningiomas. Their findings could help guide evolving diagnostic criteria and clinical trial design: jamanetwork.com/journals/jam...
@ucsfradonc.bsky.social

This recent study in #NatureCommunications showed that #STING activation induces cytotoxic and immune responses in #meningiomas via inflammatory cell death pathways.

Read the full article here: go.nature.com/3OlX42T

The role of #AdjuvantFractionatedRadiotherapy after gross total resection of WHO-2 #meningiomas remains unclear. This recent article aimed to estimate the effect of aFRT on recurrence risk and survival following GTR and subtotal resection: bit.ly/4dvhrF5

Our #ICOM members are continually working on important #research to advance our understanding and treatment of #meningiomas.

Here are a few recent articles from our members.

Can an #AI-trained program predict specific #genomic and #epigenomic patterns in #meningiomas, and can it extract more prognostic information out of standard hematoxylin and eosin histopathology than the current WHO classification?

Read the full article: bit.ly/3N7Tjxx

Read the recent study in #NatureCommunications which analyzes #meningiomas without driver mutations or major chromosomal alterations and identifies a subset with recurrent genomic rearrangements involving the #FOS and #FOSB genes.

go.nature.com/4paaVXr

Our #ICOM members are engaged in pursuing cutting-edge research on #meningiomas.

Here are some of their articles that have been published in the past few months.

Dr. Michael Lim will be speaking about the Natural History of #Meningiomas at our upcoming ICOM/NASBS Meningioma Education Day.

Dr. Lim is the Chair of the Department of #Neurosurgery at @StanfordMed and a neurosurgeon specializing in #BrainTumors and #TrigeminalNeuralgia.

Grade 2 #meningiomas often recur after surgery and #radiation therapy. However, large, in-depth failure analyses are lacking. This article reports a pattern of #FailureAnalysis, encompassing treatment and outcome data from over two decades:

bit.ly/3LONt3z

@felixehretmd.bsky.social

This meta-analysis, aiming to re-evaluate clinicopathologic data of #pediatric #meningiomas and their correlation with treatment and patient outcomes, is now available as an #AcceptedManuscript in #NeuroOncology #Pediatrics:

bit.ly/4pU95tj

Meningiomas Subset’s Genetic Drivers Identified A team of Yale researchers, led by Zeynep Erson-Omay, PhD, assistant professor in the Department of Neurosurgery, and Murat Gunel, MD, chair of the Department

A distinct subgroup of #meningiomas driven by gene fusions has been identified by Yale Cancer Center researchers. The unique molecular features & low-grade behavior offer new insights that expand classification and open new avenues for targeted treatment strategies.
medicine.yale.edu/news-article...

Read the new article in #NatureMedicine evaluating the efficacy of #abemaciclib, a cyclin-dependent kinase 4/6 inhibitor, for #meningiomas with somatic NF2 or CDK pathway alterations.

go.nature.com/4jL77cZ

MSN

www.msn.com/en-ca/health... Women suing Pfizer over Depo Provera causing a 500 percent increase in the likelihood of developing brain tumours - meningiomas - warning label has been added by the FDA. Lawsuits all over the world. #braintumours #meningiomas #depoprovera #pfizer #lawsuits

‘Analysis of anatomical location, mitoses, and Ki-67 in 2608 #meningiomas’ is now out in the Journal of #Neuropathology & Experimental #Neurology:

bit.ly/44TsLWr

As we welcome a new year, we extend our deepest gratitude to our global community dedicated to advancing understanding and care for #meningiomas.

May 2026 bring shared discoveries and strengthened partnerships in our mission to improve outcomes for all affected by meningiomas.

Read the poster ‘Natural history and surgical outcomes of single-centre experience in management of #SphenoOrbital #meningiomas‘ from the 2025 Canadian #NeuroOncology Meeting:

bit.ly/4hjt2Xv

Read about the first study to comprehensively define the molecular landscape of #meningiomas treated with #Radiotherapy in a prospective clinical trial in #NeuroOncology Advances:

bit.ly/4okYUNK

This recent article found that #mesothelin is a viable CAR T-cell target for #meningiomas, and mesothelin-specific CAR T-cell therapy shows strong preclinical efficacy.

Read more in #NeuroOncology:

bit.ly/43bm94Q

Read the poster presentation in #NeuroOncology around a new study showing that preoperative #PET imaging may significantly adjust and extend resection boundaries in #meningiomas, particularly in cases of skull base and #IntraosseousMeningiomas.

bit.ly/3IIgVqr

An older but insightful article by some #ICOM members, highlighting diagnostic challenges of #meningiomas from the #neuroimaging and #neuropathological side, presenting scientific achievements & studies potentially helping in overcoming these challenges:

academic.oup.com/neuro-oncolo...

A new article in @BrainTumourOrg highlights the findings from the Lancet Oncology paper ‘Analysis of TERT association with clinical outcome in #meningiomas: a multi-institutional cohort study’

bit.ly/46CpXhN

Meet #ICOM member Clara Lopez, a biologist and PhD student driven by a passion for #CancerResearch. From Spain to New Zealand’s Gillies McIndoe Research Institute, she explores #meningiomas to unlock new drug treatments. Outside the lab, she loves playing frisbee with friends.

This new study highlights the role of #NOTCH3 in mediating fatty acid oxidation in #meningiomas, and a potential mechanism for increased malignant potential of NOTCH3 + meningiomas.

bit.ly/42dfxTc

What are the correlations between surface marker patterns in #meningiomas, prognosis, and location?

Read more about this recent research in the Journal of Clinical Neuroscience: bit.ly/4mAcTOD

This study provides regional insight into the molecular landscape of #meningiomas. It found while routine molecular profiling adds value to classification and prognostication, broader implementation may be limited by cost and panel coverage constraints.

bit.ly/3Iuq71e

This new review and analysis reveals that #meningiomas can significantly impact #CognitiveFunction, affecting various domains such as memory, executive function, attention, and language. Most of these domains seem to improve postoperatively.

bit.ly/4nn0RJb

Dr Linda Bi, Dr Ruchit Patel, Dr Chloe Gui, Dr Farshad Nassiri, and Dr Matija Snuderl joined the #Lancet #Oncology “In Conversation with” #podcast to discuss their new papers on #TERTexpression and TERT promoter mutations in #meningiomas.

Listen now: www.thelancet.com/multimedia/p...

#ICOM & some of our members just published an article investigating the prevalence & prognostic association of #TERT expression in #meningiomas, with implications for diagnosis & treatment: bit.ly/4g8L0LZ

@gelarehzadeh.bsky.social @justinzwang.bsky.social @felixehretmd.bsky.social @syip.bsky.social

📢 New research from @pmresearch-uhn.bsky.social reveals that TERT expression—even without mutations—may signal more aggressive #meningiomas than grading suggests.

Challenging the current grading system, these findings could reshape how we treat these tumours.

🔗: www.uhnresearch.ca/news/better-...

#BAP1-altered #meningiomas represent a distinct and aggressive CNS tumor subtype associated with PRC dysregulation and recurrent 3p chromosome loss. These findings support the designation “meningioma, BAP1-altered.”

Read full article in #NeuroOncology:

bit.ly/3YWa1CN